What happened with SIBN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
SI-BONE supplies implants that surgeons use to fuse dysfunctional or degenerated sacroiliac joints, fix and fuse the spine, and treat pelvic trauma. Medical groups, hospitals and other medical facilities pay for the implants used in surgery; SI-BONE supplies the surgical instrument trays without a separate charge. Its sales representatives and independent agents bring these products to customers. Most revenue comes from U.S. customers and the iFuse implant family, including iFuse 3D, iFuse TORQ and iFuse Bedrock Granite.
Sales depend on physicians choosing these procedures and implants, and on insurers covering the procedures at adequate reimbursement rates. Its historically core sacroiliac procedures receive broad Medicare and private-insurer reimbursement, while more limited and uncertain coverage for another procedure type has affected demand for iFuse INTRA X.
SI-BONE relies on outside manufacturers, with RMS Company the sole supplier of iFuse 3D, iFuse TORQ and iFuse TORQ TNT implants. It also generally needs FDA clearance or approval before selling new regulated devices or making significant changes to existing ones, and its promotion must stay within authorized uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond adoption of sacroiliac and spinal procedures, SI-BONE depends on RMS Company, its sole supplier of iFuse 3D, iFuse TORQ and iFuse TORQ TNT implants.
Alphatec Holdings competes with SI-BONE to win surgeons and hospital purchases of spine implants and fixation systems. Watch adoption of Alphatec’s procedure-specific products for signs of competition for spinal procedure share.
Globus Medical competes with SI-BONE for hospital purchases of spine and sacroiliac implants, while its surgical navigation and robots can influence which implants hospitals choose. Watch hospital adoption of those surgery-assistance systems for signs of how difficult it may be for SI-BONE to win implant orders.
Tenon Medical’s Catamaran and SImmetry+ systems compete directly with SI-BONE’s implants for sacroiliac joint fusion procedures, with healthcare facilities buying the products. Sales of those two systems offer a focused view of competition in SI-BONE’s core procedure market.
Xtant Medical and SI-BONE compete for overlapping surgical customers buying fixation products for spinal and sacroiliac conditions. Xtant sells through agents and distributors with access to hospital networks and purchasing groups; watch its spinal fixation business rather than its biologics used in a wider range of procedures.
Orthofix Medical competes for the surgical customers SI-BONE is pursuing as it expands its spinal fusion and fixation implants. Its Global Spine sales, which include implant sales and marketing service fees, are the relevant line to watch rather than its limb reconstruction business.
Medtronic competes with SI-BONE for sacroiliac and spinal fixation purchases, and its broader surgical offering can influence hospital contracts and surgeon choice. Watch whether hospitals choose bundled surgical products, which SI-BONE says can make it harder to win their business.
Carlsmed and SI-BONE both depend on spinal fusion activity and surgeon adoption: Carlsmed sells personalized implants placed between vertebrae to hospitals and ambulatory surgical centers, while SI-BONE sells spinal and pelvic fixation implants. Watch growth in Carlsmed’s aprevo surgeon user base and use by existing surgeons for a read on adoption of advanced implants.
Alphatec Holdings, Inc. earningsATEC
Alphatec’s report will show whether surgeons and hospitals are adopting its spine implants, a direct signal of competition for the customers SI-BONE is pursuing.
Focus on Alphatec’s spine business and adoption of its procedure-specific products, rather than earnings per share alone. Growth alongside broader adoption would suggest it is winning more procedures and implant orders from surgeons and hospitals SI-BONE also pursues. Slower growth or stalled adoption would mean less evidence of competitive pressure from Alphatec, not proof that SI-BONE won those orders.
SI-BONE, Inc. earningsThis company
SI-BONE earns most of its revenue when surgeons use its implants, and this report will show whether procedure growth is holding up alongside the gross margin on those sales.
Read the number of physicians performing SI-BONE procedures and procedures per physician alongside revenue growth and gross margin. If both physician activity measures rise while gross margin holds or improves, adoption is broadening without an evident sacrifice in price or product mix. If revenue grows but gross margin falls, discounts or a less favorable mix may be diluting the value of those additional sales.
Tenon Medical, Inc. earningsTNON
Tenon Medical’s report will show whether its sacroiliac fusion systems are gaining sales, giving SI-BONE a direct read on competition in its core procedure market.
Look for sales growth in Tenon’s Catamaran and SImmetry+ systems. Rising sales would indicate that more facilities may be choosing Tenon for the same core sacroiliac fusion procedures SI-BONE serves, making Tenon a more active competitor for those cases. Flat or falling sales would show no evidence of Tenon gaining adoption, but would not establish that SI-BONE is taking share.
